HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Prescription To OTC Switch Poland OTC Drugs

Poland Gives Green Light To Switches From Teva and Polpharma

  • News

Executive Summary

Teva and Polpharma's OTC operations in Poland are set to received a boost with the approval of two switches by national medicines regulator URPL. Polish consumers can now get OTC access to additional treatments for hay fever and cough. 

You may also be interested in...



Poland Switches from Rx-To-OTC Mylan's Duspatalin For IBS, Plus Orion's ED Treatment

Poland's medicines regulator has approved the switch of Mylan's Duspatalin and Orion's Valinger.

Bayer Launches Clarinaze Allergy Control Following Successful Rx-to-OTC Switch In UK

Having received the green light for its prescription-to-OTC switch, Bayer is launching in UK pharmacies Clarinaze Allergy Control backed by a £1m marketing campaign.

Poland Kick Starts 2019 With Three Rx-To-OTC Switches

Clotrimazole, pyrantel, and ciclopirox olamine have been switched from prescription-to-OTC status by Poland's national drug regulator.

Table

View full table

Topics

Tags:
Prescription To OTC Switch Poland OTC Drugs
Latest Headlines

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

Cosmetic And Personal Care Trademark Review: 16 April

Health And Wellness Weekly Trademarks Review: 16 April

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

See All
UsernamePublicRestriction

Register

RS149010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By